Predict your next investment

Corporate Venture
FINANCIAL | Investment Firms & Funds
kpventures.com

See what CB Insights has to offer

Investments

152

Portfolio Exits

38

Funds

7

Partners & Customers

1

Service Providers

1

About Kaiser Permanente Ventures

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, invests in medical devices, health care services and health care information technology companies.

Kaiser Permanente Ventures Headquarter Location

One Kaiser Plaza 22nd Floor

Oakland, California, 94612,

United States

510-267-7300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Kaiser Permanente Ventures Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kaiser Permanente Ventures Rank

Research containing Kaiser Permanente Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Kaiser Permanente Ventures in 2 CB Insights research briefs, most recently on Dec 9, 2019.

Latest Kaiser Permanente Ventures News

Welsh, Carson, Anderson & Stowe Acquires Majority Stake in Leiters, A 503B Outsourced Pharmaceutical Compounding Industry Leader, in Partnership with Leading Health Systems

Nov 10, 2021

Welsh, Carson, Anderson & Stowe Acquires Majority Stake in Leiters, A 503B Outsourced Pharmaceutical Compounding Industry Leader, in Partnership with Leading Health Systems -- WCAS, Intermountain Ventures, Novant Health, Rex Health Ventures, Spectrum Health Ventures and UNC Health join Leiters' existing investors, including Kaiser Permanente Ventures and Mayo Clinic -- DENVER and NEW YORK, November 9, 2021-- Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today it has acquired a majority ownership stake in Leiters, a rapidly growing leader in the FDA-regulated 503B outsourced pharmaceutical compounding industry. WCAS acquired its equity position in Leiters from the Company's existing investor group, which includes strategic health system partners Kaiser Permanente Ventures and Mayo Clinic and financial sponsors Frazier Healthcare Partners, SV Health Investors and H.I.G. BioHealth Partners. All the existing investors, including Kaiser Permanente Ventures and Mayo Clinic, have made significant reinvestments in the Company as part of this transaction. They are joined by Intermountain Ventures, Novant Health, Rex Health Ventures, Spectrum Health Ventures and UNC Health, who invested alongside WCAS in support of Leiters' growth strategy. The Company's health system investors, along with other industry leaders, will participate in a strategic advisory committee to support growth initiatives, continuous quality improvement, new product development and investments in enabling capabilities. Leiters provides high-quality compounded sterile preparations across the continuum of healthcare to hospitals, surgery centers and physician offices. In 2014, Leiters registered with the FDA as a 503B outsourcer and has since undergone a significant transformation including: a new management team with extensive experience in pharmaceutical-grade sterile manufacturing; the completion of its state-of-the-art automated sterile manufacturing facility in Denver; and a significant broadening of its product portfolio into new categories. The Company is currently undergoing a significant facility expansion as part of the upcoming introduction of its new IV Solutions product line and offers an end-to-end suite of product types including pre-filled syringes, IV bags and concentrated vials; pain services including opioid free medications; pharmacy fill service for the ON-Q* Pain Relief System; and ophthalmic medications and services including, FDA-Compliant Repackaged Avastin®. As part of an ongoing commitment to, and investment in, quality, compliance and manufacturing excellence, Leiters continues to invest in and deploy automation throughout its operation including automated syringe, IV bags and ON-Q* filling machines, as well as fully automated inspection, labeling and packaging capabilities. These investments exponentially increase capacity and ensure the continued delivery of high-quality medications to the healthcare market. In addition, Leiters is pursuing an additional facility to facilitate growth and expand capabilities for its customers. Nick O'Leary, General Partner at WCAS, said, "We are very excited about our investment in Leiters. The Company is a leader in 503B outsourcing and is recognized as having one of the highest-quality operations in the industry, where quality and patient safety are paramount. Leiters represents a compelling opportunity for WCAS to leverage its capabilities in two areas where we have developed significant domain expertise: pharmaceutical services and successful collaboration with leading health systems. We are especially pleased about the opportunity to work in close partnership with some of the most forward-thinking health systems in the country as well as Leiters' CEO, Robin Smith Hoke, who is an exceptional leader." Robin Smith Hoke, Leiters' President and Chief Executive Officer said, "We very much welcome WCAS as Leiters' majority investor. WCAS is one of the preeminent healthcare investors and we have full confidence that their team will bring a wealth of relevant experience as we continue to build for the future. Their expertise in healthcare and deep relationships throughout the industry will allow Leiters to continue its transformative path. I am thrilled about the momentum we have established in our business and look forward to driving our next chapter of growth. We will continue to focus on elevating industry standards and believe our relationship with WCAS and our health system partners will accelerate our growth and fuel innovation." Cantor Fitzgerald & Co. served as financial advisor to Leiters in connection with the transaction. About Leiters Leiters is a trusted FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. It is committed to providing healthcare professionals and their patients with critically needed outsourced medications. Its team of experts in sterile pharmaceutical manufacturing, repackaging and compounding provide a sophisticated understanding of what it takes to elevate quality and consistency of supply in pharmaceutical outsourcing. Leiters combines a highly experienced team, with robust automated processes, in a state-of-the-art outsourcing facility, to ensure delivery of the highest quality medicines. All sterile preparations are produced under the Human Drug Outsourcing Facilities under 503B of the FD&C Act (503B Guidance) and follow Current Good Manufacturing Practices (cGMP). To learn more about how Leiters is Compounding Health™ please visit www.leiters.com. About Welsh, Carson, Anderson & Stowe WCAS is a leading U.S. private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. The firm has raised and managed funds totaling over $27 billion of committed capital. For more information, please visit www.wcas.com. Contact:

Kaiser Permanente Ventures Investments

152 Investments

Kaiser Permanente Ventures has made 152 investments. Their latest investment was in Genome Medical as part of their Series C on August 8, 2021.

CBI Logo

Kaiser Permanente Ventures Investments Activity

investments chart

Kaiser Permanente Ventures Portfolio Exits

38 Portfolio Exits

Kaiser Permanente Ventures has 38 portfolio exits. Their latest portfolio exit was Ginger on August 25, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/25/2021

Merger

8

6/29/2021

Acq - Fin

2

12/7/2020

Acquired

$991

6

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/25/2021

6/29/2021

12/7/2020

00/00/0000

00/00/0000

Exit

Merger

Acq - Fin

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

2

6

10

10

Kaiser Permanente Ventures Fund History

7 Fund Histories

Kaiser Permanente Ventures has 7 funds, including Kaiser Permanente Ventures V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/5/2019

Kaiser Permanente Ventures V

Multi-Stage Venture Capital

$141M

3

6/30/2008

KP Healthcare Fund V

Subscribe to see more

$99M

10

10/1/2006

Kaiser Permanente Healthcare Fund IV

Subscribe to see more

$99M

10

3/30/2005

Kaiser Permanente Healthcare Fund III

Subscribe to see more

$99M

10

7/31/2004

Kaiser Permanente Healthcare Side Fund

Subscribe to see more

$99M

10

Closing Date

12/5/2019

6/30/2008

10/1/2006

3/30/2005

7/31/2004

Fund

Kaiser Permanente Ventures V

KP Healthcare Fund V

Kaiser Permanente Healthcare Fund IV

Kaiser Permanente Healthcare Fund III

Kaiser Permanente Healthcare Side Fund

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$141M

$99M

$99M

$99M

$99M

Sources

3

10

10

10

10

Kaiser Permanente Ventures Partners & Customers

1 Partners and customers

Kaiser Permanente Ventures has 1 strategic partners and customers. Kaiser Permanente Ventures recently partnered with Unite Us on May 5, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

5/30/2019

Partner

Unite Us

United States

Event Recap – Community-Wide Collaboration Between the Health Care & Social Sectors - KP Ventures

To read more about the Unite Us partnership with Kaiser Permanente Ventures on Thrive Local , please read here .

1

Date

5/30/2019

Type

Partner

Business Partner

Unite Us

Country

United States

News Snippet

Event Recap – Community-Wide Collaboration Between the Health Care & Social Sectors - KP Ventures

To read more about the Unite Us partnership with Kaiser Permanente Ventures on Thrive Local , please read here .

Sources

1

Kaiser Permanente Ventures Service Providers

1 Service Provider

Kaiser Permanente Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Kaiser Permanente Ventures Team

2 Team Members

Kaiser Permanente Ventures has 2 team members, including current Managing Director, Amy Belt Raimundo.

Name

Work History

Title

Status

Amy Belt Raimundo

Evidation, Covidien Ventures, Medtronic, and Advanced Technology Ventures

Managing Director

Current

Liz Rockett

Managing Director

Current

Name

Amy Belt Raimundo

Liz Rockett

Work History

Evidation, Covidien Ventures, Medtronic, and Advanced Technology Ventures

Title

Managing Director

Managing Director

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.